Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer, Inc.    PFE

PFIZER, INC.

(PFE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/14/2020 09/15/2020 09/16/2020 09/17/2020 09/18/2020 Date
37.01(c) 36.96(c) 36.78(c) 36.82(c) 36.63(c) Last
28 050 836 20 876 431 21 105 953 16 977 605 29 612 440 Volume
+2.61% -0.14% -0.49% +0.11% -0.52% Change
More quotes
Financials (USD)
Sales 2020 48 906 M - -
Net income 2020 13 460 M - -
Net Debt 2020 35 205 M - -
P/E ratio 2020 17,4x
Yield 2020 4,14%
Sales 2021 53 531 M - -
Net income 2021 14 093 M - -
Net Debt 2021 22 362 M - -
P/E ratio 2021 14,4x
Yield 2021 4,31%
Capitalization 204 B 204 B -
EV / Sales 2020 4,88x
EV / Sales 2021 4,22x
Nbr of Employees 88 300
Free-Float 59,1%
More Financials
Company
Pfizer, Inc. the world's leading pharmaceutical group. Net sales break down by family of products as follows: - biopharmaceuticals (76.2%): innovative drugs for the treatment of cancer, inflammatory, autoimmune, infectious, metabolic, cardiovascular and rare diseases, vaccines, etc. In addition, the group develops an active pharmaceutical ingredient manufacturing activity; - generic pharmaceutical products (19.8%;... 
Sector
Pharmaceuticals
Calendar
09/20Presentation
More about the company
Notations Surperformance© of Pfizer, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about PFIZER, INC.
09/19PFIZER : Correction to Midwest Coronavirus Case Numbers Article on Sept. 18
DJ
09/18Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk -study
RE
09/18Coronavirus Case Numbers Stay Elevated in Parts of Midwest--4th Update
DJ
09/18When will COVID-19 vaccines be generally available in the U.S.?
RE
09/18Coronavirus Case Numbers Stay Elevated in Parts of Midwest -- 3rd Update
DJ
09/18Coronavirus Case Numbers Stay Elevated in Parts of Midwest--2nd Update
DJ
09/18Moderna sees 20 million doses of COVID-19 vaccine candidate by year end
RE
09/18Coronavirus Case Numbers Stay Elevated in Parts of Midwest -- Update
DJ
09/18PFIZER : Thinking about buying stock in Westport Fuel Systems, General Electric,..
PR
09/18EXCLUSIVE : Fearing supply shortfall, EU wants to buy more COVID vaccines - EU s..
RE
09/18PFIZER : BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine P..
AQ
09/18PFIZER : PhRMA - Coming together to fight COVID-19, a conversation with Albert B..
AQ
09/18Coronavirus Case Numbers Stay Elevated in Parts of Midwest--Update
DJ
09/18Coronavirus Case Numbers Stay Elevated in Parts of Midwest
DJ
09/17Pfizer vaccine trial bets on early win against coronavirus, documents show
RE
More news
News in other languages on PFIZER, INC.
09/18Trump promet qu'il y aura assez de vaccins pour tous les Américains d'ici avr..
09/17CORONAVIRUS : deux fabricants américains de vaccins dévoilent les règles
09/17Wall Street termine dans le rouge après un nouveau repli de la tech
09/17BioNTech baut Produktionskapazitäten für Corona-Impfstoff deutlich aus
09/17Bourse Zurich: toujours morose, malgré un léger mieux
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 42,63 $
Last Close Price 36,63 $
Spread / Highest target 50,2%
Spread / Average Target 16,4%
Spread / Lowest Target -4,45%
EPS Revisions
Managers
NameTitle
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Wyllie Don Cornwell Independent Director
Suzanne Nora Johnson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER, INC.-6.02%203 549
JOHNSON & JOHNSON2.27%392 765
ROCHE HOLDING AG9.27%322 209
MERCK & CO., INC.-5.65%217 034
NOVARTIS AG-9.76%200 978
NOVO NORDISK A/S12.50%161 415